For research use only. Not for therapeutic Use.
TP-0903（Cat No.:I001303）is a potent inhibitor of AXL receptor tyrosine kinase, a key player in cancer cell survival, proliferation, metastasis, and drug resistance. By targeting AXL, TP-0903 disrupts the signaling pathways that promote tumor growth and immune evasion. It has shown significant promise in preclinical studies, particularly for treating cancers with high AXL expression, such as acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC). TP-0903 is also being explored for its potential to enhance the effectiveness of immunotherapies, making it a valuable candidate in cancer treatment strategies.
| Catalog Number | I001303 |
| CAS Number | 1341200-45-0 |
| Synonyms | (E)-2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4(3H)-ylidene)amino)-N,N-dimethylbenzenesulfonamide |
| Molecular Formula | C₂₄H₃₀ClN₇O₂S |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | DMSO: ≥ 30 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | 2-[[5-chloro-2-[4-[(4-methylpiperazin-1-yl)methyl]anilino]pyrimidin-4-yl]amino]-N,N-dimethylbenzenesulfonamide |
| InChI | InChI=1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29) |
| InChIKey | YUAALFPUEOYPNX-UHFFFAOYSA-N |
| SMILES | CN1CCN(CC1)CC2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)N(C)C)Cl |
| Reference | 1:Leuk Lymphoma. 2016;57(6):1494-7. doi: 10.3109/10428194.2015.1102243. Epub 2015 Nov 16. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.Patel V,Keating MJ,Wierda WG,Gandhi V, PMID: 26440741 PMCID: PMC4963009 [Available on 2017-06-01] DOI: 10.3109/10428194.2015.1102243 |
